Pharma: Other News To Note
Friday, March 23, 2012
GlaxoSmithKline plc, of London, said it plans to invest more than £500 million (US$790.9 million) in its UK manufacturing sites to increase production of key active ingredients for its pharmaceutical products and vaccines. The company said it will build a £350 million biopharmaceutical manufacturing facility at Ulverston, Cumbria, and invest more than £100 million across two manufacturing sites in Scotland.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.